Drink product containing genistein and use thereof

Abstract

A drink product having as an active ingredient genistein and an inositol hexaphosphate and/or an unphosphorylated inositol and optionally additional inositol (unphosphorylated as well as hexaphosphorylated) moieties. Hexaphosphates for use in the invention include myoinositol hexaphosphate and/or any of the other 8 optical isomers thereof. The optional additional inositols include myoinositol and/or any of the other 8 optical isomers thereof. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed.

1 . An aqueous liquid formulation comprising:
 (a) water and   (b) myoinositol hexaphosphate and/or an optical isomer thereof, and/or an orally acceptable salt thereof,   (c) Genistein   (d) further optionally comprising one or more components selected from the group consisting of:
 (1) myoinositol and/or optical isomer; 
 (2) an orally acceptable free radical scavenger other than Genistein; 
 (3) a nutritionally acceptable orally administrable electrolyte; 
 (4) a nutritionally acceptable orally administrable vitamin; 
 (5) a flavor; 
 (6) an orally administrable coloring agent; 
 (7) an orally administrable sweetener; 
 (8) an oral formulation acceptable thickener; 
 (9) an orally administrable, liquid formulation processing aid; and, 
 (10) an orally administrable, liquid formulation auxiliary carrier other than water. 
   
     
     
         2 . A method of reducing the risk of damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         3 . A method of preventing damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         4 . A method of treating damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         5 . A method of reducing the risk of developing HIV and/or AIDS and secondary cancers related to HIV and AIDS comprising orally administering the formulation of  claim 1 . 
     
     
         6 . The method of  claim 5  wherein said cancers related to HIV and AIDS is selected from Kaposi sarcoma and non-Hodgkin lymphoma, Hodgkin disease and cancers of the lung, mouth, skin, cervix, and digestive system, liver, blood, soft tissue, and muscular tumors. 
     
     
         7 . A method of preventing a HIV/AIDS related cancer selected from breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, colon cancer liver, cervical, uterine, liver, blood, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         8 . A method of treating a cancer selected from Kaposi sarcoma and non-Hodgkin lymphoma, other AIDS-related cancers selected from Hodgkin disease and cancers of the lung, mouth, skin, cervix, and digestive system, liver blood, soft tissue, and muscular tumors breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, coln cancer liver, cervical, uterine, liver, blood, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         9 . A method of increasing T cells and or inhibiting HIV related CD4 reduction comprising administering the composition of  claim 1  to a subject in need thereof 
     
     
         10 . A method for blocking the communication between a HIV cell surface to internal cellular compartment comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         11 . A method for preventing an HIV particle from entering the internal cellular compartments thereby preventing the spread of the infection comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         12 . A method of reducing the risk of adverse effects of common and current drug toxicities' associated with current anti-viral therapies comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         13 . A method of reducing drug resistance comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         14 . A method for both prevention HIV infection of resting CD4 T-cells, viral DNA synthesis, and/or viral nuclear migration comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         15 . A method for preventing Gag-Na inositol does that interactions prior to membrane binding in HIV comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         16 . A method for inhibiting the replication of HIV-1 comprising administering the composition of  claim 1  to a subject in need thereof 
     
     
         17 . A method for AP3B1 regulation and HIV-1 Gag release comprising administering the composition of  claim 1  to a subject in need thereof. 
     
     
         18 . The product of  claim 1  which is a liquid nutritional supplement. 
     
     
         19 . The product of  claim 1  which is an orally administered product. 
     
     
         20 . A method of reducing the risk of damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 1 . 
     
     
         21 - 30 . (canceled)